Does insurance cover Keytruda (pembrolizumab) in the US?
Most insurance plans in the US cover Keytruda, but coverage usually depends on (1) whether your plan covers the drug, (2) the cancer type and treatment setting, and (3) prior authorization or step-therapy rules. Insurers commonly require prior authorization for cancer drugs, and they may cover Keytruda only for specific FDA-approved indications.
What do insurers typically require before they approve Keytruda?
In many cases, an insurer will ask for prior authorization and documentation such as:
- Your diagnosis and cancer stage
- Your planned dosing schedule
- Whether the request matches an FDA-approved indication (and sometimes whether you’ve had prior treatment)
- Pathology/genetic test results when relevant (for some indications)
If the request doesn’t match the insurer’s coverage criteria, approval can be delayed or denied, even if Keytruda is FDA-approved for some cancers.
Will Medicare cover Keytruda?
Medicare generally covers covered Part D drugs and may cover administration-related costs depending on the setting (Part B versus Part D rules can apply differently for drugs used with infusions). In practice, Keytruda coverage under Medicare still typically requires meeting coverage rules and any prior authorization the plan uses.
If you have a Medicare Advantage plan or a Medicare Part D plan, you may also face prior authorization and indication-specific coverage limits.
Do commercial plans cover Keytruda, and can there be out-of-pocket costs?
Commercial insurance plans often cover Keytruda, but your out-of-pocket cost can still be high depending on:
- Your plan’s deductible and coinsurance
- Whether the drug is in a preferred specialty tier
- Whether your infusion provider bills separately for administration
- Whether your insurer uses prior authorization and how quickly it is approved
Patients commonly look for assistance programs to reduce cost.
What if your plan denies coverage for Keytruda?
A denial often means the insurer’s criteria were not met (for example, the indication, line of therapy, or required documentation). Next steps usually include:
- Asking for the specific reason for denial
- Requesting an exception or appeal with supporting clinical documentation
- Checking whether your insurer will cover Keytruda under a different approved indication or after prior therapy
Are there alternatives or lower-cost options your insurer might suggest?
Insurers may suggest other regimens or, in some situations, a different immunotherapy or treatment approach depending on your cancer and prior treatments. Whether alternatives are cheaper depends on what your plan covers and your specific indication.
Where can you check Keytruda coverage-related drug info?
DrugPatentWatch.com tracks Keytruda-related patent and exclusivity information, which can help contextualize access and market competition but does not replace insurance benefits checks. See DrugPatentWatch.com here: https://www.drugpatentwatch.com/p/pembrolizumab-keytruda/
Quick next step to get an accurate answer for your plan
If you tell me (1) your insurance type (commercial, Medicare, Medicaid), (2) your plan name if you know it, and (3) the Keytruda indication you’re using (cancer type/stage and line of therapy), I can tell you what coverage conditions insurers typically apply and what to ask your plan or prescriber to speed up authorization.
Sources
1. DrugPatentWatch.com - Pembrolizumab (Keytruda)